Navigation Links
Pharmexa in Medical Technology

Pharmexa A/S (DK) - Pharmexa presents data from influenza program

Summary: Pharmexa-Epimmune, the U.S.-based subsidiary of Pharmexa A/S, presents selected data from its influenza vaccine program today at the Influenza Conference entitled, "Options for the Control of Influenza VI," held in Toronto, Ontario, Canada. The data show that a "universal" vaccine designe...

Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine

...with low royalty stacking. The Company has concluded deals with commercial organizations such as Peregrine, XOMA, NatImmune, Viventia, Dyax, Micromet, pharmexa and others. Further information at www.affitech.com. Contact Affitech (Norway) Dr. Martin Welschof Chief Executive Officer +47 22 95 87 58 <...

Pharmexa A/S (DK) - Long lasting immune response and survival to RAS vaccine

...f Executive Officer, telephone +45 4516 2525 Claude Mikkelsen, Head of Investor Relations, telephone +45 4516 2525 or +45 4060 2558 Note to editors: pharmexa A/S is a leading company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. Pharm...
Pharmexa in Biological Technology

Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech

... Affitech A/S is an antibody research and development company. It was formed recently by a reverse merger of Norway, Oslo-based Affitech AS with pharmexa A/S, a Danish biotech company. The merged company has developed several proprietary technology platforms that constitute a highly productive, fully h...

Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company

... COPENHAGEN and OSLO, March 4 /PRNewswire/ -- pharmexa A/S and Affitech AS announced today that they have...anies by means of a share for share acquisition by pharmexa A/S of the private Norwegian company, Affitech AS. The purpose of the merger is to transform pharmexa from a cancer and infectious disease vaccine busin...

Affitech Acquires Pharmexa's Diabody Technology

...ndidates for a variety of therapeutic applications. The acquisition follows an exclusive license of the diabody IP that Affitech obtained in 2007 from pharmexa to carry out certain non-clinical GLP compliant studies, as well as sub-licensing arrangements with third parties. Affitech CEO Martin Welschof comm...

Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration

...y stacking. The Company has concluded deals with commercial organizations such as Omeros, Roche, Peregrine, XOMA, NatImmune, Viventia, Dyax, Micromet, pharmexa and others. Further information at http://www.affitech.com . Contacts for Affitech: Affitech (Norway): Dr. Martin Welschof Chief Executive Off...

Affitech Appoints Dr. Keith McCullagh as Chairman

...y stacking. The Company has concluded deals with commercial organizations such as Roche, Peregrine, Omeros, XOMA, NatImmune, Viventia, Dyax, Micromet, pharmexa and others. Further information at http://www.affitech.com . About Keith McCullagh Keith McCullagh, PhD, BVSc, MRCVS, is an experienced bioscienc...

Emergence of Cancer Vaccines Will Be the Key Factor Driving the Pancreatic Cancer Drug Market to More Than Double by 2016

...orld's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the emergence of cancer vaccines, including drugs from pharmexa and Cell Genesys, will be the key factor driving the pancreatic cancer drug market to more than double by 2016. The new Pharmacor report entitled Pan...
Other Tags
(Date:4/18/2014)... researchers have been awarded two-year grants for their work ... month. Of the 110 initial submissions to the new ... only four projects were funded, three of which are ... M.D., Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, ... oncology, will use his $500,000 proof of principle grant ...
(Date:4/18/2014)... French . ... regenerative medicine. A team led by Ludwik Leibler from ... and Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle ... that the principle of adhesion by aqueous solutions of ... organs and tissues. This easy-to-use gluing method has been ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... recent papers by a University of Colorado School ... develop treatments or vaccines for Dengue fever, West ... disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, associate ... School of Medicine and an early career scientist ... recently published articles in the scholarly journals ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
(Date:4/17/2014)... have hit on a novel method to help ... and most effective treatment possible., Kidney stones represent ... developing world. If left untreated, apart from being ... and other complications. In many patients treated successfully, ... more effective pathological approach to diagnosis and treatment ...
(Date:4/17/2014)... meeting painted a stark warning on the possible effects ... greenhouse effect 32 times that of carbon dioxide. Now ... substances act as fully regenerable electron acceptors which helps ... wetlands instead of being released to the atmosphere. However, ... it may enter into a vicious cycle to release ...
(Date:4/17/2014)... Indiana University researchers have detected new early-warning signs of ... discovery could have far-reaching implications for the diagnosis and ... over 25 million Americans. , "We had not expected ... such early stages," said Ann Elsner, professor and associate ... author of the study. "We set out to study ...
Breaking Biology News(10 mins):Methane climate change risk suggested by proof of redox cycling of humic substances 2New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
Other Contents